Skip to content

Study · Non-randomized trial · n = 6 · 1989

6 results

Modification of 24-hour growth hormone secretion after continuous subcutaneous infusion of growth hormone-releasing hormone (GHRH (1-29)NH2) in short children with low 24-hour growth hormone secretion.

Tauber MT, Pienkowski C, Landier F, Gunnarsson R, Rochiccioli P

Acta paediatrica Scandinavica. Supplement1 Jan 1989Cited by 2 (Europe PMC)

PMID2546370 (opens in a new tab)DOI10.1111/j.1651-2227.1989.tb17182.x (opens in a new tab)PepBankPUB-02546370
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In six short children with low 24-hour GH secretion, all parameters of 24-hour GH secretion increased during GHRH(1-29)NH2 infusion.

    In plain wordsIn six short children with low growth hormone release, all measures of 24-hour growth hormone release rose during GHRH infusion, with no control group.

    Peptide
    Sermorelin
    Outcome
    Increase24-hour GH secretion parameters
    Study

    n = 6

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · subcutaneous infusion · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    All parameters of 24-hour GH secretion increased
    1 context sentence
    Summary · context
    Six short children with low 24-hour growth hormone (GH) secretion were treated with continuous subcutaneous infusion of GHRH (1-29)NH2 for 3 weeks using a portable infusion pump.
  2. 02HumanNon-randomized trialPharmacokinetics

    In short children, plasma GHRH(1-29)NH2 levels were significantly higher on day 21 than on day 1 of infusion, suggesting altered pharmacokinetics over time.

    In plain wordsIn short children, GHRH levels in blood were higher on day 21 than on day 1 of the infusion.

    Peptide
    Sermorelin
    Outcome
    IncreasePlasma GHRH(1-29)NH2 level on day 21 versus day 1
    Study

    n = 6

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · subcutaneous infusion · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    Plasma levels of GHRH (1-29)NH2 were significantly higher on day 21 than on day 1 of treatment, suggesting altered pharmacokinetics over time.
    1 context sentence
    Summary · context
    Six short children with low 24-hour growth hormone (GH) secretion were treated with continuous subcutaneous infusion of GHRH (1-29)NH2 for 3 weeks using a portable infusion pump.
  3. 03HumanNon-randomized trialEfficacy outcome

    In five of six short children, the GH response was greater on day 1 than on day 21 of GHRH(1-29)NH2 treatment.

    In plain wordsIn five of six short children, the growth hormone response was smaller on day 21 than on day 1 of GHRH infusion.

    Peptide
    Sermorelin
    Outcome
    DecreaseMagnitude of GH response on day 21 versus day 1
    Study

    n = 5

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · subcutaneous infusion · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    but in five children the magnitude of the GH response was greater on day 1 than on day 21 of GHRH treatment.
    1 context sentence
    Summary · context
    Six short children with low 24-hour growth hormone (GH) secretion were treated with continuous subcutaneous infusion of GHRH (1-29)NH2 for 3 weeks using a portable infusion pump.
  4. 04HumanNon-randomized trialEfficacy outcome

    In short children with low 24-hour GH secretion, GHRH(1-29)NH2 at 40 micrograms/kg/day restored pulsatile GH secretion in all three children treated.

    In plain wordsIn short children with low growth hormone release, a higher GHRH dose restored pulsatile growth hormone release in all three treated, with no control group.

    Peptide
    Sermorelin
    Outcome
    IncreaseRestoration of pulsatile GH secretion at 40 micrograms/kg/day
    Study

    n = 3

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    40 micrograms/kg/day · subcutaneous infusion · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    Restoration of pulsatile GH secretion was observed in all three children treated with 40 micrograms/kg/day of GHRH
    1 context sentence
    Summary · context
    Six short children with low 24-hour growth hormone (GH) secretion were treated with continuous subcutaneous infusion of GHRH (1-29)NH2 for 3 weeks using a portable infusion pump.
  5. 05HumanNon-randomized trialEfficacy outcome

    In short children with low 24-hour GH secretion, GHRH(1-29)NH2 at 20 micrograms/kg/day restored pulsatile GH secretion in only one of three children.

    In plain wordsIn short children with low growth hormone release, a lower GHRH dose restored pulsatile release in only one of three children, with no control group.

    Peptide
    Sermorelin
    Outcome
    MixedRestoration of pulsatile GH secretion at 20 micrograms/kg/day
    Study

    n = 3

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    20 micrograms/kg/day · subcutaneous infusion · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    but in only one of the three children treated with 20 micrograms/kg/day.
    1 context sentence
    Summary · context
    Six short children with low 24-hour growth hormone (GH) secretion were treated with continuous subcutaneous infusion of GHRH (1-29)NH2 for 3 weeks using a portable infusion pump.
  6. 06HumanNon-randomized trialEfficacy outcome

    In the single child who responded to 20 micrograms/kg/day of GHRH, the GH response was greater after 21 days of treatment than on day 1.

    In plain wordsIn the one child who responded to the low GHRH dose, the growth hormone response was larger after 21 days than at the start.

    Peptide
    Sermorelin
    Outcome
    IncreaseGH response in the single low-dose responder on day 21
    Study

    n = 1

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    20 micrograms/kg/day · subcutaneous infusion · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    This decrease was not observed in the single child who responded to a low dose of GHRH (20 micrograms/kg/day); on the contrary, the response in this patient was greater after 21 days of GHRH treatment.
    1 context sentence
    Summary · context
    Six short children with low 24-hour growth hormone (GH) secretion were treated with continuous subcutaneous infusion of GHRH (1-29)NH2 for 3 weeks using a portable infusion pump.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 10:21 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.